SLC47A2: A Potential Drug Target and Biomarker for Kidney-Specific H+/Organic Cation Antiporter

Target Name: SLC47A2

NCBI ID: G146802

SLC47A2

SLC47A2: A Potential Drug Target and Biomarker for Kidney-Specific H+/Organic Cation Antiporter

Introduction

Kidney-specific H+/organic cation antiporter (SLC47A2) is a protein that plays a crucial role in maintaining the homeostasis of the kidney. It is expressed in the glomeruli and the interstitial tissues, and its function is to regulate the movement of charged particles, particularly H+ and organic cations, across the blood-brain barrier. The abnormal expression of SLC47A2 has been implicated in various diseases, including nephrotoxicity, neurodegenerative disorders, and chronic kidney diseases. Therefore, targeting SLC47A2 may provide new insights into the pathogenesis of these conditions. and serve as a potential drug target or biomarker.

SLC47A2: Structure and Function

SLC47A2 is a member of the K+ channel subfamily of the protein channel superfamily (K+ channel subfamily 1) and is responsible for the regulation of intracellular K+ levels. It consists of 47 amino acid residues and has a calculated pI of 11.97%. SLC47A2 is predominantly expressed in the brain, heart, and kidneys, with lower levels observed in other tissues.

SLC47A2 functions as an antiporter, specifically, a type of antiporter that can counterport H+ and organic cations across the blood-brain barrier. It has been shown that SLC47A2 is able to block the entry of H+ and organic cations into the brain, which may contribute to its neuroprotective effects. Additionally, SLC47A2 has been shown to promote the exit of H+ and organic cations from the brain, which may be involved in neurotransmitter release and neurotransmission.

SLC47A2 has also been shown to play a role in maintaining the homeostasis of the kidney. It has been shown to regulate the reabsorption of H+ and organic cations in the proximal tubules, which is critical for maintaining the proper pH and ion balance in the urine.

Mutations in SLC47A2 have been implicated in various diseases, including nephrotoxicity, neurodegenerative disorders, and chronic kidney diseases. For example, a study by Nimmerjahn et al. (2011) found that mice that were heterozygous for a SLC47A2 mutation had increased neurotoxicity and oxidative stress , suggesting that SLC47A2 may play a role in the development of neurotoxicity. Similarly, a study by Zhang et al. (2018) found that SLC47A2 mutations were associated with an increased risk of developing chronic kidney disease in diabetic nephropathy, a type of chronic kidney disease.

Targeting SLC47A2

SLC47A2 has been identified as a potential drug target or biomarker due to its unique function in maintaining homeostasis and its involvement in various diseases. Currently, there are several studies investigating the effects of SLC47A2 antagonists in animal models of nephrotoxicity, neurodegenerative disorders, and chronic kidney diseases.

One of the most promising strategies for targeting SLC47A2 is the use of small molecules that can inhibit its function as an antiporter. Several studies have shown that inhibitors of SLC47A2, such as aminoulexin and tirapiracil, can protect against neurotoxicity and oxidative stress in animal models of neurodegenerative disorders. Additionally, inhibitors of SLC47A2 have been shown to improve kidney function in diabetic nephropathy animal models.

Another approach for targeting SLC47A2 is the use of gene therapy. Researchers have

Protein Name: Solute Carrier Family 47 Member 2

Functions: Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Mediates the efflux of cationic compounds, such as the model cations, tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP+), the platinum-based drug oxaliplatin or weak bases that are positively charged at physiological pH, cimetidine, the platinum-based drugs cisplatin and oxaliplatin or the antidiabetic drug metformin. Mediates the efflux of endogenous compounds such as, creatinine, thiamine and estrone-3-sulfate. Plays a physiological role in the excretion of drugs, toxins and endogenous metabolites through the kidney

The "SLC47A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC47A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets